ClinicalTrials.gg
CompletedNCT00572559Updated Jun 9, 2010

Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus

A Phase 4 interventional study of Vancomycin and Linezolid in Pneumonia, Ventilator-Associated, sponsored by Pfizer. Completed at 37 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-06-09.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 62 studies in Pneumonia, Ventilator-Associated with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Pneumonia, Ventilator-Associated · United States.

Enrollment
25th of 49
149 · median 149
Started
2002
with 2 others
Phase 4
7 of 62
none open now
Registered
13th of 62
by date
Lead sponsor
3 of 62
Pfizer

Among the 62 studies in Pneumonia, Ventilator-Associated with a site in United States, this one is the 25th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2002, is one of 7 in phase 4, and was the 13th registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

4 of the 62 studies in Pneumonia, Ventilator-Associated with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Pneumonia, Ventilator-Associated with a site in United States, or all of them as a file.
02

Study summary

Ventilator-associated pneumonia (VAP) is a commonplace complication of intensive care patients ventilated for longer than 48 hours. Methicillin-resistant Staphylococcus aureus (MRSA) is the cause of late onset VAP in up to about 30% of cases in US hospitals. Ineffective treatment of MRSA VAP clearly leads to prolonged mechanical ventilation and is probably associated with higher mortality. The purpose of this protocol is to directly compare linezolid and vancomycin specifically for MRSA VAP.

03

Conditions studied

  • Pneumonia, Ventilator-Associated
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient must have or be suspected of having a ventilator-associated pneumonia (VAP) due to MRSA.
  • Patient must be hospitalized for at least 5 days, must be ventilator-dependent ≥ 48 hours prior to screen/baseline, and anticipated to remain on the ventilator for 72 hours after enrollment so follow-up BAL can be performed.
  • Clinical picture compatible with pneumonia (acquired during ventilation)
  • Chest X Ray at baseline/screen or within 24 hours of initiation of therapy must be consistent with diagnosis of pneumonia

Exclusion criteria

Exclusion Criteria:

  • to linezolid, vancomycin, or one of the in any of these drug formulations.
  • Infections due to gram-positive organisms known to be resistant to either of the study drugs.
  • Any antibiotic used in the treatment of MRSA, such as vancomycin, TMP/SMX, rifampin, or linezolid, for more than 48 hours prior to patient's enrollment into the study.
  • Patients with neutropenia, AIDS, lymphoma or anticipated chemotherapy.
  • Patients who have long-term tracheostomy (for more than 60 days). Acute tracheostomy patients are allowed.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    1

    Drug: Vancomycin

  • Experimental
    2

    Drug: Linezolid

Interventions

  • 1 gram IV every 12 hours for 7 to 14 days

  • 600 mg every 12 hours (intravenously \[IV\] for a minimum of the first 4 days followed by a switch to oral if tolerated by patient) for a total duration of 7 to 14 days

06

What researchers measure

Primary outcomes

  1. To assess early microbiologic response in patients with VAP due to MRSA based on semi-quantitative culture of bronchoscopic bronchoalveolar lavage (BAL) in patients treated with linezolid vs vancomycin.

    Time frame: 72-96 hours

Secondary outcomes

  1. To compare duration of mechanical ventilation

    Time frame: 0000

  2. To compare post treatment tracheal colonization

    Time frame: FU: 14 days after EOT +/- 2 days

  3. To identify clinical correlates of infection based on microbiologic sampling as determined by original and modified CPIS (Clinical Pulmonary Infection Score)

    Time frame: EOT: Day 14; FU: 14 days after EOT +/- 2 days

  4. To compare the microbiological cure based on BAL specimens with the traditional criteria for microbiologic cure

    Time frame: 72-96 hours

  5. To compare mortality at End Of Treatment (EOT) and Follow up (FU); To compare clinical outcome at EOT and FU

    Time frame: EOT: Day 14; FU: 14 days after EOT +/- 2 days

07

Study locations

37 sites
  • Pfizer Investigational Site
    Phoenix, Arizona 85006, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85012, United States
  • Pfizer Investigational Site
    Palm Springs, California 92262, United States
  • Pfizer Investigational Site
    Rancho Mirage, California 92270, United States
  • Pfizer Investigational Site
    Redlands, California 92373, United States
  • Pfizer Investigational Site
    Sacramento, California 95819, United States
  • Pfizer Investigational Site
    Sacramento, California 95829, United States
  • Pfizer Investigational Site
    Norwalk, Connecticut 06850, United States
  • Pfizer Investigational Site
    Waterbury, Connecticut 06708, United States
  • Pfizer Investigational Site
    Waterbury, Connecticut 06721, United States
  • Pfizer Investigational Site
    Augusta, Georgia 30909, United States
  • Pfizer Investigational Site
    Decatur, Georgia 30033, United States
  • Pfizer Investigational Site
    North East Atlanta, Georgia 30308, United States
  • Pfizer Investigational Site
    North East Atlanta, Georgia 30322, United States
  • Pfizer Investigational Site
    North East Atlanta, Georgia 30329, United States
  • Pfizer Investigational Site
    Ewa Beach, Hawaii 96706, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60612, United States
  • Pfizer Investigational Site
    Peoria, Illinois 61603, United States
  • Pfizer Investigational Site
    Peoria, Illinois 61636, United States
  • Pfizer Investigational Site
    Peoria, Illinois 61637, United States
  • Pfizer Investigational Site
    Lexington, Kentucky 40536, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40206, United States
  • Pfizer Investigational Site
    Bronx, New York 10467, United States
  • Pfizer Investigational Site
    Buffalo, New York 14215, United States
  • Pfizer Investigational Site
    Cortland Manor, New York 10567, United States
  • Pfizer Investigational Site
    Jamaica, New York 11418, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45267-0559, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38103, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38104, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38163, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37212-3375, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
  • Pfizer Investigational Site
    Spokane, Washington 99204, United States
  • Pfizer Investigational Site
    Spokane, Washington 99216, United States
  • Pfizer Investigational Site
    Spokane, Washington 99220, United States
  • Pfizer Investigational Site
    Morgantown, West Virginia 26505, United States
  • Pfizer Investigational Site
    San Juan, 00921-3201, Puerto Rico
08

References and documents

Publications

  • Wunderink RG, Mendelson MH, Somero MS, Fabian TC, May AK, Bhattacharyya H, Leeper KV Jr, Solomkin JS. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest. 2008 Dec;134(6):1200-1207. doi: 10.1378/chest.08-0011. Epub 2008 Aug 21. PubMed 18719064 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2007
First posted
Dec 13, 2007
Start
Nov 2002
CompletionActual
Jan 2005
Last update
Jun 9, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00572559
Lead sponsor
Pfizer
First posted
Dec 13, 2007
Start date
Nov 2002
Completion
Jan 2005
Last update
Jun 9, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vancomycin · Linezolid

Start the discussion